ArticleLupus science & medicine2026
Unveiling the molecular and immune heterogeneity across distinct disease activity states of systemic lupus erythematosus through integrative bulk and single-cell transcriptomics.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by substantial variability in clinical presentations and disease severity. This study aims to investigate the molecular and cellular mechanisms underlying distinct SLE Disease Activity Index (SLEDAI)-defined disease states of SLE and to identify potential prognostic biomarkers and therapeutic targets associated with heightened inflammatory activity.
methodsWe analysed bulk and single-cell RNA sequencing datasets from SLE patients. Patients were stratified into clinically distinct SLEDAI-defined disease states using established SLEDAI thresholds, which served as operational surrogates of inflammatory disease burden. Differentially expressed genes and gene co-expression networks were analysed to identify severity-associated hub genes. The immune microenvironment and intercellular communication were evaluated using CIBERSORTx and CellChat algorithms, respectively.
resultsDifferential expression and network analyses identified five key hub genes (KLRK1, IL2RB, RAG1, SH2D1B and NCR1) strongly correlated with SLE disease activity states, which were used to develop a five-gene SLE severity (SLEsev) score. The SLEsev score was significantly higher in high-activity/severe SLE (sSLE) compared with low-activity/mild SLE (mSLE) (p<0.001), which showed a consistent trend in an independent validation cohort. Immune profiling revealed that mSLE was enriched in regulatory T cells (Tregs) and memory B cells, whereas sSLE exhibited elevated levels of CD8+T cells, natural killer cells and monocytes (p<0.05). Single-cell analysis demonstrated that sSLE possessed a more complex cellular communication network (311 vs 283 inferred interactions) and greater overall interaction strength than mSLE, with prominent pro-inflammatory signalling pathways such as IFN-II, GAS and CCL playing a key role in sSLE.
conclusionsThis study unveils the profound immunological and transcriptomic dysregulation underlying SLE severity. The identified five-gene SLEsev score serves as a potential biomarker for disease stratification, while the hyperactive intercellular signalling networks highlight specific molecular targets for modulating immune responses in severe SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.